ProMIS Neurosciences

ProMIS Neurosciences

ProMIS Neurosciences was founded in 2014 by Dr. Neil Cashman and colleagues, rooted in two decades of academic work on protein misfolding disorders at the University of British Columbia and the University of Toronto. The company's foundational insight is that neurodegenerative diseases share a common mechanism — the formation of toxic, misfolded protein oligomers. Rather than targeting broad protein aggregates, ProMIS isolates and neutralizes the specific epitopes driving toxicity. CEO Neil Warma, who took the helm in 2022, restructured the pipeline around this core thesis. The company's lead candidate, PMN310, is a humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers believed to drive Alzheimer's progression. A Phase 1b clinical trial for PMN310 in mild-to-moderate Alzheimer's patients is underway, with early biomarker data suggesting target engagement without the ARIA side effects that have plagued competing antibodies. ProMIS also maintains a tau program and has explored applications in Parkinson's disease and ALS, though Alzheimer's remains the near-term focus. The company's antibody discovery relies on a proprietary computational platform that models protein misfolding pathways and predicts the conformational epitopes unique to toxic oligomers. This computational biology engine generates highly specific therapeutic candidates, a precision approach that distinguishes ProMIS from competitors using broader-target antibodies. ProMIS has historically operated a lean R&D model, leveraging academic collaborations and contract research organizations rather than building large internal infrastructure. In addition to its own pipeline, ProMIS entered a research collaboration with a large pharmaceutical partner in 2018 to apply its platform to an undisclosed neurodegenerative target, generating non-dilutive capital. The firm has also explored out-licensing opportunities for its tau and TDP-43 programs to preserve Alzheimer's focus. Geographically, the company's executive and R&D operations are split between Toronto and Cambridge, Massachusetts, reflecting its academic roots in Canada and its regulatory-facing presence in the US biotech corridor. ProMIS trades on the Nasdaq under the ticker PMN, with a market capitalization below $50 million as of early 2025, leaving it well outside the large-cap biotech universe. The company has not passed the proof-of-concept inflection point that would typically attract institutional biotech specialists, though it has secured funding from a mix of retail investors and niche healthcare funds. In July 2023, ProMIS completed a 1-for-10 reverse stock split to maintain Nasdaq listing compliance, a move that underscored the financial constraints of a preclinical-stage CNS drug developer in a tight capital market. The firm also appointed Dr. Larry Altstiel as Chief Medical Officer in 2023, bringing late-stage Alzheimer's development experience from the Lilly donanemab program. ProMIS does not operate philanthropic foundations or adjacent investment vehicles; it is a pure-play drug development company with no family-office or asset-management affiliate. ProMIS's structural distinction lies in its epitope-specific targeting strategy. While the FDA approved Biogen's aducanumab and Lilly's donanemab validated the amyloid hypothesis, both drugs carry a risk of ARIA and target a broad swath of amyloid species. ProMIS argues that its oligomer-specific approach can deliver efficacy with a cleaner safety profile — a thesis that will face its first real clinical test when PMN310 Phase 1b data read out. The company's computational platform also represents a genuine technical differentiator in a field where antibody selection has historically relied on immunization and screening rather than predictive modeling.